Minerva medica
-
Antiandrogen therapy can reduce the expression of transmembrane protease 2, which is essential for severe acute respiratory syndrome coronavirus-2 to enter the host cells. Prior trials suggested the efficacy of antiandrogen agents in patients with COVID-19. We investigated whether antiandrogen agents reduce mortality compared to placebo or usual care. ⋯ Antiandrogen therapy reduced mortality and clinical worsening in adult patients with COVID-19.
-
A meta-analysis was carried out to systematically evaluate the effects of liraglutide on waist circumference, BMI, weight, insulin resistance (IR), Follicle-Stimulating Hormone (FSH), and Luteinizing hormone (LH) levels in obese women with polycystic ovarian syndromes (PCOS). ⋯ For women with PCOS, BMI, weight, and waist circumference were significantly decreased after 12~24 weeks of treatment with liraglutide monotherapy and add-on therapy. Insulin resistance might be improved with the use of liraglutide. Nevertheless, large scale randomized control trials should be carried out to elucidate the long-term outcome in improving the insulin sensitivity of liraglutide treatment.
-
Novel treatments target eosinophilic inflammation in type 2 asthma. We aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate. ⋯ Monoclonal antibodies have proven their benefit to reduce exacerbation rates in severe persistent eosinophilic asthma in the published trials. No biological showed superiority over the others emphasizing the need for clearly defined endotypes indicating those patients who will optimally benefit for each treatment.
-
This study is a meta-analysis of the published studies on the relationship between methylenetetrahydrofolate reductase (MTHFR) C667T polymorphism and the risk of late- onset Alzheimer 's disease (LOAD) in Italian cohorts. ⋯ The present meta-analysis showed only trend of association between MTHFR C677T polymorphism and LOAD in Italian population; however, it also demonstrated an increased susceptibility of LOAD in patients having MTHFR 677TT genotype. Further studies are needed to establish whether MTHFR polymorphisms can be used as non-invasive biomarker for LOAD.